48
44
| Cat. No. | Product Name | ||
|---|---|---|---|
| L9200 | 药物功能重定位化合物库 | 4240 compounds | |
| 4240种全球上市药物和临床药物的独特集合，可用于高通量筛选和高内涵筛选，是老药新用、新的药物靶点筛选和细胞诱导的有效工具。 | |||
| LF1000 | 预制多样性库 | 50000 compounds | |
| For your convenience, there are Diversity Sets of 5,000, 10,000, 15,000, and 20,000 compounds with no structure overlap. | |||
| L1000 | 上市药物库 | 2863 compounds | |
| 2863个上市药物化合物集合，可用于高通量筛选和高内涵筛选； | |||
| L7820 | 高溶解性微型片段化合物库 | 1082 compounds | |
| 高溶解性微型片段化合物库由 1082 个低分子量片段组成。 | |||
| L8110 | 细胞重编程化合物库 | 1840 compounds | |
| 1840种重编程信号通路相关的生物活性小分子化合物的特有集合，可用于高通量、高内涵筛选 | |||
| L3900 | DNA 损伤和修复分子库 | 937 compounds | |
| 937个与DNA损伤和修复紧密相关的化合物集合，是高通量筛选，高内涵筛选的良好载体； | |||
| L6010 | 天然产物库 | 3720 compounds | |
| 3720种天然产物的独特集合，可用于高通量筛选和高内涵筛选； | |||
| L3980 | DNA损伤/修复库Plus | 667 compounds | |
| 667种DNA损伤/修复靶向、结构新颖的化合物； | |||
| L1700 | 抗病毒库 | 800 compounds | |
| 800种具有抗病毒活性的化合物的特有集合，是筛选新型抗病毒药的有效工具；可用于高通量筛选和高内涵筛选； | |||
| L2190 | 抗肺癌化合物库 | 1735 compounds | |
| 1735种与肺癌相关的化合物，可以用于抗肺癌药物研发和药理研究； | |||
| L2400 | 内分泌激素分子库 | 813 compounds | |
| 813种与内分泌系统相关的生物活性小分子化合物的特有集合，用于高通量、高内涵筛选； | |||
| L1200 | 表观遗传库 | 960 compounds | |
| 960种表观遗传学研究相关的生物活性小分子的特有集合，用于表观遗传学研究及其相关的检测和高通量、高内涵筛选； | |||
| L4510 | 抗寄生虫库 | 336 compounds | |
| 336种具有抗寄生虫活性，且结构新颖的小分子化合物； | |||
| L2180 | 抗肿瘤库Plus | 1468 compounds | |
| 1468种抗肿瘤相关、结构新颖的化合物； | |||
| L1300 | PI3K/Akt/mTOR 化合物库 | 425 compounds | |
| 425种与PI3K/Akt/mTOR相关的生物活性小分子化合物的特有集合，用于PI3K/Akt/mTOR相关研究以及高通量、高内涵筛选； | |||
| L2610 | 神经递质受体化合物库 | 1513 compounds | |
| 1513种与神经递质受体相关的化合物，用于高通量、高内涵筛选； | |||
| L9600 | 多肽分子库 | 533 compounds | |
| 533种多肽类分子，可用于多肽药物开发及信号转导通路和作用机制研究； | |||
| L2620 | 神经退行性疾病化合物库 | 1622 compounds | |
| 1622种与神经退行性疾病相关的化合物，可用于高通量和高内涵筛选； | |||
| L2600 | 神经信号分子库 | 2011 compounds | |
| 2011种CNS相关的生物活性小分子化合物的特有集合，用于高通量、高内涵筛选； | |||
| L2160 | 抗癌活性化合物库 | 2439 compounds | |
| 2439种具有抗肿瘤活性的化合物的特有集合，用于高通量、高内涵筛选； | |||
| L4600 | 植物来源化合物库 | 2720 compounds | |
| 2720个植物来源天然产物的独特集合，来自277类植物的精心之选； | |||
| L9300 | 大环化合物库 | 155 compounds | |
| 155种活性已知的大环化合物，用于高通量、高内涵筛选； | |||
| L6220 | 蒙药化合物库 | 960 compounds | |
| 960种蒙药来源的天然产物分子集合，可以用于高通量和高内涵筛选； | |||
| L6900 | 稀有天然产物库 | 284 compounds | |
| 284种稀有天然产物的集合，可以用于高通量和高内涵筛选； | |||
| L6710 | 中药抗炎分子库 | 1040 compounds | |
| 1040种具有抗炎活性或靶向炎症相关靶点的中药单体集合，是药物开发、药理研究的有效工具； | |||
| L9840 | 抗阿尔茨海默症化合物库 | 1040 compounds | |
| 1040 种阿尔茨海默症相关的化合物集合，可用于高通量和高内涵筛选； | |||
| L4020 | NO PAINS 化合物库 | 9555 compounds | |
| TargetMol NO PAINS 化合物库包含 9555 个剔除了PAINS的小分子活性化合物，可用于新药研发，信号通路研究，老药新用等研究。 | |||
| L8400 | 血液病分子库 | 524 compounds | |
| 524种造血系统疾病相关的生物活性小分子化合物的特有集合，用于高通量、高内涵筛选； | |||
| L2191 | 抗乳腺癌化合物库 | 1965 compounds | |
| 1965种与乳腺癌相关的化合物，可以用于抗乳腺癌药物研发和药理研究； | |||
| L3200 | 自噬库 | 1248 compounds | |
| 1248种细胞自噬相关的生物活性小分子化合物的特有集合，用于自噬相关的研究，用于高通量、高内涵筛选； | |||
| L6200 | 瑶药化合物库 | 225 compounds | |
| 225种瑶药来源的天然产物分子集合，可以用于高通量和高内涵筛选； | |||
| L2510 | 脂代谢化合物库 | 496 compounds | |
| 496个脂代谢相关的化合物集合，可用于高通量和高内涵筛选； | |||
| L9500 | 表型筛选靶点鉴定库 | 1832 compounds | |
| 1832种靶点明确的已知活性化合物，适合表型筛选； | |||
| L5510 | 肝脏毒性化合物库 | 1040 compounds | |
| 1040个肝脏毒性化合物的特有集合，可用于高通量、高内涵筛选，是毒理学研究的良好工具； | |||
| L4300 | Wnt/Hedgehog/Notch 通路化合物库 | 240 compounds | |
| 240个Wnt & Hedgehog & Notch靶点相关的生物活性小分子化合物的特有集合，用于相关通路的研究及药物的筛选，可用于高通量、高内涵筛选。 | |||
| L7100 | 抗肥胖化合物库 | 1359 compounds | |
| 1359个抗肥胖化合物的独特集合，可用于高通量筛选和高内涵筛选； | |||
| L4800 | 血管生成库 | 1370 compounds | |
| 1370个高潜力的抑制或促进血管生成的小分子集合，可用于药物靶点开发、血管生成机理研究的高通量筛选，高内涵筛选； | |||
| L6800 | 中国药典收录天然产物库 | 2070 compounds | |
| 2070种中国药典收录的天然产物，是药物开发、药理研究等领域的有力工具； | |||
| L2170 | 肿瘤免疫治疗小分子化合物库 | 454 compounds | |
| 454种靶向肿瘤免疫治疗靶点的小分子，可用于高通量和高内涵筛选，是研究肿瘤免疫治疗的有力工具； | |||
| L1010 | FDA上市及药典收录分子库 | 3158 compounds | |
| 3158个上市及药典分子集合，可用于高通量筛选和高内涵筛选； | |||
| L4520 | 抗菌活性库 | 921 compounds | |
| 921种具有抗菌活性的化合物，是抗菌药物研发的有力工具； | |||
| L8710 | 铜死亡化合物库 | 411 compounds | |
| TargetMol 铜死亡化合物库集合了 411 种与铜死亡相关的化合物，可以用于铜死亡机制及相关疾病研究 | |||
| L4000 | 经典已知活性库 | 12862 compounds | |
| 12862个已知活性化合物的集合，可用于高通量筛选、高内涵筛选、细胞诱导和靶点确认； | |||
| L1500 | GPCR靶点分子库 | 1633 compounds | |
| 1633种与G蛋白及其耦联受体相关的生物活性小分子化合物，所有小分子都具有良好的生物和药理活性，部分是FDA批准的上市药物； | |||
| Cat. No. | Product Name | Target | Signaling Pathways |
|---|---|---|---|
| TN6408 | New compound 6 | ||
| Reference standards. | |||
| TN6550 | New compound 2 | ||
| TN6434 | New compound 4 | ||
| Reference standards. | |||
| TN6410 | New compound 3 | ||
| TN6407 | New compound 5 | ||
| Reference standards. | |||
| T27819 |
Levonantradol hydrochloride
Levonantradol HCl; CP 50,556-1; CP-50,556-1 |
||
| Levonantradol hydrochloride is a new compound with antiemetic activity. | |||
| T60454 | NDM-1 inhibitor-3 | ||
| NDM-1 inhibitor-3 (Compound 89) 是一种 New Delhi Metallo-β-lactamase-1 (NDM-1) 抑制剂(Ki = 4 μM)。New Delhi Metallo-β-lactamase-1 (NDM- 1)，是一种获得性金属碳青霉烯酶，于 2009 年首次报道，目前被认为是开发对产生 NDM 的临床分离株具有活性的 β-内酰胺-β-内酰胺酶抑制剂组合的最具临床相关性的靶标之一。 | |||
| TN3218 | 7-(4-Hydroxyphenyl)-1-phenyl-4-hepten-3-one | Beta Amyloid; PI3K; mTOR | PI3K/Akt/mTOR signaling; Neuroscience |
| 7-(4-Hydroxyphenyl)-1-phenyl-4-hepten-3-one as a beneficial compound to ameliorate the deleterious effects of Aβ on dendrite integrity and cell survival, and may provide new insights on drug discovery of Alzheimer's disease (AD). | |||
| T60925 | TRβ agonist 3 | ||
| TRβ agonist 3 (Compound 3) 是TRβ的有效激动剂，它是一种新的潜在 TRβ 选择性拟甲状腺素。在体外研究中，TRβ agonist 3 可减少 HepG2 中的脂质积累并促进脂肪分解。 | |||
| T61464 | TRβ agonist 2 | ||
| TRβ agonist 2 (Compound 1) 是一种有效的TRβ激动剂。TRβ agonist 2 可减少 HepG2 中的脂质积累并促进脂解作用，效果相当。TRβ agonist 2 是一种新的潜在 TRβ 选择性拟甲状腺素。 | |||
| T60477 | Haspin-IN-1 | ||
| Haspin-IN-1 (compound 2a) 是一种haspin（单倍体生殖细胞特异性核蛋白激酶）抑制剂，IC50值为 119 nM。Haspin-IN-1 还抑制CLK1、DYRK1A 和 CDK9，IC50分别为 221 nM 、916.3 nM和406.8 nM。Haspin-IN-1具有开发新型抗癌药物的潜力[1]。 | |||
| T60286 | DHFR-IN-2 | ||
| DHFR-IN-2 (化合物 4e) 是一种有效且非竞争性的MtDHFR抑制剂，其IC50值为 7 μM。来自结核分枝杆菌 (MtDHFR) 的二氢叶酸还原酶具有很高的未开发潜力，可以成为抗结核病 (TB) 新药的靶标，因为它对病原体存活很重要。DHFR-IN-2可用于结核病(TB)研究。 | |||
| T36316 | MTOR inhibitor-8 | ||
| mTOR inhibitor-8 is an mTOR inhibitor and autophagy inducer. mTOR inhibitor-8 inhibits the activity of mTOR via FKBP12 and induces autophagy of A549 human lung cancer cells[1]. mTOR inhibitor-8 (Compound 5e; 0.1-10 μM; 24 and 48 hours) suppresses the growth of A549 cells in a dose-dependent manner[1].mTOR inhibitor-8 induces autophagy in an mTOR-dependent manner. mTOR inhibitor-8 (10 μM; 3-24 hours) induces autophagy in a time-dependent manner. The levels of LC3B-II are enhanced[1].mTOR inhibit... | |||
| T37690 | Phenylpyropene A | ||
| Phenylpyropene A is a fungal metabolite originally isolated from P. griseofulvum that has enzyme inhibitory and insecticidal activities.1,2,3 It inhibits acyl-coenzyme A:cholesterol acyltransferase (ACAT; IC50 = 0.8 μM).1 Phenylpyropene A inhibits diacylglycerol acyltransferase (DGAT) in rat liver microsomes (IC50 = 78.7 μM). It induces mortality in 100% of M. persicae when used at a concentration of 5 ppm.3 |1. Kwon, O.E., Rho, M.C., Song, H.Y., et al. Phenylpyropene A and B, new inhibitors of ... | |||
| T25361 | Ecomustine | ||
| Ecomustine is a new antitumor compound. | |||
| T25307 |
Denzimol hydrochloride
REC 15-1533 |
||
| Denzimol hydrochloride is a new anticonvulsant compound. | |||
| T13483 |
RP 54275
2-Octadecyl-1H-indole-5-carboxylic acid |
Others | Others |
| RP 54275 is a new hypocholesterolemic compound. | |||
| T25764 |
LY 81067
Lilly81067; LY81067; LY-81067; Lilly 81067; Lilly-81067 |
||
| LY 81067 is a new anticonvulsive compound. | |||
| T13609L | Chlorazanil | Others | Others |
| Chlorazanil, a triazine derivative, is a new nonmercurial diuretic compound. | |||
| T25498 | Hexapradol | ||
| Hexapradol is a new antiulcer compound with a cytoprotective action. | |||
| T14296 | Antitumor agent-3 | Others | Others |
| Antitumor agent-3 is a potent compound. It comprises a new imidazopyridine having excellent antitumor activity as an active ingredient. | |||
| T1832 | Walrycin B | Antibacterial; Antibiotic | Microbiology/Virology |
| Walrycin B是一种能特异地靶向WalR应答调节子的新型抗菌素。 | |||
| T27376 |
FR-186054
FR 186054; FR186054 |
||
| FR-186054 is a new, potent inhibitor of acyl-CoA:cholesterol O-acyltransferase (ACAT) and has oral activity. Compared to other ACAT inhibitors, this compound displayed excellent in vitro efficacy, irrespective of dosing method, indicating superior charact | |||
| T63825 | Antiallergic agent-1 | ||
| Antiallergic agent-1 是一种Src 家族激酶抑制剂，可能作为未来抗过敏药物发现的一种新的有价值的先导化合物。 | |||
| T29979 |
Amidantel hydrochloride
BAY-d 8815; BAY d 8815 |
||
| Amidantel hydrochloride is a new aminophenylamidine with an interesting anthelminthic spectrum. In rodents the compound is active against nematodes, filariae and cestodes. Of special interest is the high efficacy in dogs against hookworms and large roundw | |||
| T39638 | Eprodisate | ||
| Eprodisate is a new compound designed to interfere with interactions between amyloidogenic proteins and glycosaminoglycans and thereby inhibit polymerization of amyloid fibrils and deposition of the fibrils in tissues. Eprodisate slow the progression of AA amyloidosis-related renal disease and has possible applicability to other types of amyloidosis. | |||
| T29979L |
Amidantel free base
Amidantel; BAY d8815; BAY d 8815; BAYd-8815; BAY d-8815; BAYd 8815 |
||
| Amidantel free base is a new aminophenylamidine with an interesting anthelminthic spectrum. In rodents the compound is active against nematodes, filariae and cestodes. Of special interest is the high efficacy in dogs against hookworms and large roundworms | |||
| T27245 |
Eflucimibe
F12511; L0081; L-0081; F-12511 |
||
| Eflucimibe is an ACAT inhibitor. Eflucimibe regulates endogenous hypercholesterolemia in a synergistic manner in New Zealand rabbits fed a casein-enriched diet. In vivo, orally administered Eflucimibe displayed high potency and efficacy as an antihypercho | |||
| T63478 | Antifungal agent 12 | ||
| Antifungal agent 12 是新型的 fluconazole 类化合物，表现出良好的抗真菌效果。 | |||
| TN2296 |
Vinaginsenoside R4
越南参皂苷R4 |
Others | Others |
| Vinaginsenoside R4 是分离自水培人参的叶子中。它能够抑制黑色素的生物合成，并增强斑马鱼的色素沉着，对 melan-a 细胞没有任何细胞毒性作用。 | |||
| T71622 | Duartin | ||
| Duartin is an anti-rickettsial compound. These small molecules and the workflow, featuring a high-throughput phenotypic screen for growth inhibitors of intracellular Rickettsia spp. and machine learning models for the prediction of growth inhibition of an obligate intracellular Gram-negative bacterium, should prove useful in the search for new therapeutic strategies to treat infections from Rickettsia spp. and other obligate intracellular bacteria. | |||
| T62486 | VIM-2-IN-1 | ||
| VIM-2-IN-1 (compound 1dj) 是一种 β-内酰胺酶 (β-lactamase) 抑制剂，具有抗菌作用。VIM-2-IN-1 能够作用于 Verona 整合子编码的金属-β-内酰胺酶 (VIM-2) (IC50: 23 μM)、德国亚胺培内酶-1 (GIM-1) (IC50: 48 μM) 和新德里金属 (NDM-1) (IC50: 231 μM)。 | |||
| T70507 | KAI-407 | ||
| KAI407 is a potent non-8-aminoquinoline compound that kills Plasmodium cynomolgi early dormant liver stage parasites in vitro. KAI407 showed an activity profile similar to that of primaquine (PQ), efficiently killing the earliest stages of the parasites that become either primary hepatic schizonts or hypnozoites (50% inhibitory concentration [IC50] for hypnozoites, KAI407, 0.69 μM, and PQ, 0.84 μM; for developing liver stages, KAI407, 0.64 μM, and PQ, 0.37 μM). KAI407 may represent a new compou... | |||
| T2035 | WHI-P258 | EGFR; JAK; JNK | Angiogenesis; Chromatin/Epigenetic; JAK/STAT signaling; MAPK; Stem Cells; Tyrosine Kinase/Adaptors |
| WHI-P258 是喹唑啉化合物，结合到JAK3的活性位点(Ki:72 µM)。甚至当WHI-P258到达 100 μM 时也不会抑制 JAK3 ，且对凝血酶诱导的血小板聚集无影响。 | |||
| T31215 |
DB-766
DB766 |
||
| DB-766 is a potential chemotherapeutic candidate for Chagas' disease treatment. DB-766 exhibits strong trypanocidal activity and excellent selectivity for bloodstream trypomastigotes and intracellular amastigotes (Y strain), giving IC(50)s of 60 and 25 nM | |||
| T5S1988 |
Isorhamnetin-3-O-glucoside
Isorhamnetin-3-O-beta-D-Glucoside; 异鼠李素-3-O-葡萄糖苷 |
Others | Others |
| Isorhamnetin-3-O-glucoside 是一种天然化合物，广泛存在于蔬菜和水稻中，经消化后可在肠道菌群中代谢。 | |||
| TWS2045 |
Bruceine D
鸦胆子素D; 鸦胆子苦素D |
Gamma-secretase; Antiviral; Apoptosis; Parasite | Apoptosis; Immunology/Inflammation; Microbiology/Virology; Neuroscience; Proteases/Proteasome; Stem Cells |
| Bruceine D 是Notch抑制剂，有抗癌活性，诱导几种人癌细胞调亡。它是一种有效的植物性昆虫拒食剂，有显著的系统特性和抑制害虫生长的作用。它具有较强的驱虫活性，抑制D. intermedius的 EC50值为 0.57 mg/L。 | |||
| TN4300 | Isojacareubin | MAPK; PKC; Antifection | Chromatin/Epigenetic; Cytoskeletal Signaling; MAPK; Microbiology/Virology |
| Isojacareubin displays potent activity against H. pylori HP40 clinical isolate with MIC 23.9 uM, which is approximately two times greater than that of the standard drug amoxicillin. Isojacareubin is a potent inhibitor of protein kinase C (PKC), suppresses | |||
| T69589 | PX-316 | ||
| PX-316 is a AKT inhibior. PX-316, when administered intraperitoneally to mice at 150 mg/kg, inhibits Akt activation in HT-29 human tumor xenografts up to 78% at 10 h with recovery to 34% at 48 h. PX-316 has antitumor activity against early human MCF-7 breast cancer and HT-29 colon cancer xenografts in mice. PX-316 formulated in 20% hydroxypropyl-beta-cyclodextrin for intravenous administration is well tolerated in mice and rats with no hemolysis and no hematological toxicity. Thus, PX-316 is the... | |||
| T5813 | BYAKANGELICIN | Reductase | Endocrinology/Hormones; Metabolism |
| Byakangelicin 是发现于当归根中的一种活性化合物，可作为调节剂，改善各种活性化合物 (Umb，Cur 和 Dox) 的脑积累，增强研究效果。它提高所有PXR靶基因 (如MDR1) 的表达，并广泛的诱导药物-药物相互作用。它可抑制性激素的作用，可能会增加内源激素的分解代谢。 | |||
| T4S21320 |
ISOGINKGETIN
异银杏素; 4',4'''-Dimethylamentoflavone; 异银杏双黄酮 |
Others; MMP | Others; Proteases/Proteasome |
| Isoginkgetin 是一种MMP9抑制剂，也是一种Pre-mRNA Splicing抑制剂。 | |||
| T29187 | YM-53403 | ||
| YM-53403 is a respiratory syncytial virus (RSV) inhibitor. YM-53403 potently inhibited the replication of RSV strains belonging to both A and B subgroups, but not influenza A virus, measles virus, or herpes simplex virus type 1. A plaque reduction assay w | |||
| T4615 |
Balsalazide sodium hydrate
巴柳氮钠水合物; 巴柳氮钠; Balsalazide disodium salt dihydrate; Balsalazide disodium; Balsalazide disodium dihydrate |
Interleukin; STAT | Immunology/Inflammation; JAK/STAT signaling; Stem Cells |
| Balsalazide sodium hydrate 可通过调节IL-6/STAT3通路起抑癌作用，可用于治疗炎症性肠病。 | |||
| T71230 | VMY-1-103 | ||
| VMY-1-103 is a potent CDK inhibitor, is also a novel dansylated analog of purvalanol B, was shown to inhibit cell cycle progression and proliferation in prostate and breast cancer cells more effectively than purvalanol B. VMY-1-103 , but not purvalanol B, significantly decreased the proportion of cells in S phase and increased the proportion of cells in G(2)/M. VMY-1-103 increased the sub G(1) fraction of apoptotic cells, induced PARP and caspase-3 cleavage and increased the levels of the Death ... | |||
| T60282 | Metallo-β-lactamase-IN-3 | ||
| Metallo-β-lactamase-IN-3 (compound 35) 是一种有效的金属 -β- 内酰胺酶 (MBL) 抑制剂，具有恢复现有 β-内酰胺类抗生素活性的潜力并为新抗生素的发现提供正交策略。Metallo-β-lactamase-IN-3 对VIM-1和NDM-1的活性较高，其IC50值分别为 0.6 和 1.0 μM。Metallo-β-lactamase-IN-3 对 IMP-7 无抑制作用。 | |||
| T37036 | HnRNPK-IN-1 | ||
| hnRNPK-IN-1 is a heterogeneous nuclear ribonucleoprotein K (hnRNPK) binding ligand with Kd values of 4.6 μM and 2.6 μM measured with SPR and MST, respectively. hnRNPK-IN-1 inhibits c-myc transcription by disrupting the binding of hnRNPK and c-myc promoter. hnRNPK-IN-1 induces Hela cells apoptosis and has strongly anti-tumor activities[1]. hnRNPK-IN-1 (Compound 25; 1.25-5 μM; 24 hours) treatment induces Hela cells apoptosis could be due to its repression of cmyc transcription[1].hnRNPK-IN-1 (1.25... | |||
| T38192 | Unifiram | Others | Others |
| Unifiram 是一种认知增强剂。 Unifiram 诱导大鼠海马 CA1 区场兴奋性突触后电位 (fEPSP) 幅度的持久增加 (EC50= 27 nM) 并增加大鼠大脑皮层中乙酰胆碱 (ACh) 的释放。 | |||
沪公网安备 31010602006700号
